Semax: Two Receptors of the Sleep Clock, One Focus Peptide

The short version

Semax is the lead compound on this desk — a small, lab-made peptide built from a fragment of adrenocorticotropic hormone (ACTH), the body's stress-response hormone, with an added tail that helps it survive longer in the body. Unlike ACTH itself, Semax does not trigger a cortisol release; instead, animal research shows it raises levels of two proteins the brain uses to grow and repair its own wiring, called BDNF and NGF ^[8][9].

It has been studied and used as a prescription medicine in Russia and Ukraine for conditions like stroke and cognitive impairment, but it has no FDA or EMA approval anywhere else, and almost all of the mechanistic evidence comes from rodent studies rather than large Western human trials. This page describes what has actually been studied, in which species, and how far that evidence reaches — it never recommends a dose or a use for any person.

What it is

Semax is a synthetic linear heptapeptide — seven amino acids — written out as H-Met-Glu-His-Phe-Pro-Gly-Pro-OH, or MEHFPGP for short. It combines the native ACTH(4-7) fragment (Met-Glu-His-Phe) with an added Pro-Gly-Pro tail grafted onto the end specifically to slow down how quickly enzymes break the peptide apart. That graft is the whole design idea: keep the piece of ACTH that seems to matter for the brain, lose the piece that raises cortisol, and add a few extra amino acids to make it last a bit longer. It is commonly supplied as the acetate salt and lacks the steroidogenic activity of full-length ACTH entirely.

How it works

The clearest, best-supported part of Semax's story is its effect on neurotrophins — proteins that act like fertilizer for brain cells, encouraging them to grow, connect, and survive. In rat studies, a single intranasal dose rapidly and specifically raised BDNF and NGF gene expression and protein levels in particular brain regions (hippocampus, basal forebrain, brainstem) within hours, and Semax was found to bind a specific, reversible site with high affinity (a dissociation constant of about 2.4 nanomolar) ^[8][9]. That specificity — a real binding site, not just noise — is one reason researchers take Semax's mechanism more seriously than DSIP's.

Semax also inhibits enzymes in human serum that normally break down enkephalins, the body's own opioid-like signaling peptides, in laboratory testing — a mechanism thought to prolong natural opioid-peptide activity rather than introduce an external opioid ^[12]. In animal models of brain injury (stroke and spinal cord injury), its protective effect looks less like a single-switch action and more like a broad shift in gene expression toward immune regulation and blood-vessel repair ^[7].

What the research shows

Spinal cord injury recovery (2025). In female mice with a T9-T10 spinal cord injury, Semax improved functional recovery and reduced a cell-death process called pyroptosis, acting through the mu-opioid receptor gene Oprm1 by way of a protein regulation pathway (USP18 and FTO deubiquitination) ^[6].

Genome-wide brain response to stroke (2014). After a permanent stroke model in rats, a genome-wide analysis found Semax predominantly reshaped immune-system genes — immunoglobulins and chemokines made up over half of all affected genes — along with a smaller set of vascular-system genes, framing immune regulation and blood-vessel effects as central to how Semax protects the brain after injury ^[7].

Rapid neurotrophin gene changes (2007). A single 50-microgram-per-kilogram intranasal dose in male rats produced fast, region-specific shifts in gene expression: NGF and BDNF messenger RNA rose in the hippocampus, BDNF rose in the brainstem and cerebellum, while NGF actually fell in the frontal cortex — a reminder that Semax's effects are not uniform across the brain ^[8].

Specific binding and neurotrophin protein rise (2006). Intranasal Semax at two doses raised BDNF protein specifically in the rat basal forebrain (not the cerebellum) within three hours, and separate binding experiments found a specific, reversible, calcium-dependent binding site with a dissociation constant of 2.4 nanomolar ^[9].

Neuroprotection in a stroke model (2006). Six days of intranasal Semax in a rat model of prefrontal-cortex ischemia reduced the size of the resulting brain injury and improved retention of a learned avoidance task — described by the researchers as an antiamnesic effect ^[10].

How fast it reaches the brain (2006). Using radiolabeled Semax, researchers found it reaches the brain within about two minutes of an intranasal dose, with roughly 80% of the radioactivity still representing intact peptide at that point and the rest already metabolized — evidence of both fast brain penetration and rapid breakdown ^[11].

Human serum enzyme inhibition (2001). In laboratory testing with human serum, Semax inhibited enkephalin-degrading enzymes with a potency (IC50 around 10 micromolar) roughly twice that of the related peptide Selank, and outperformed several reference inhibitor compounds — supporting the idea that it may prolong the body's own opioid-peptide signaling ^[12].

Reported effects, cautions & safety

People discussing Semax in nootropics and biohacker communities describe a fairly consistent daytime-focus profile, alongside an honest counterweight of non-response. These are anecdotal, not clinical evidence — self-reports from forums and community writeups, not measured outcomes — and none involve a recommended dose or route.

Reported benefits (anecdotal, not clinical evidence): the single most consistent report is a quick-onset sense of mental clarity, often within the first hour, frequently described as "focus without the jitters" and contrasted favorably with caffeine or stimulant medication. People also describe sustained focus and a "just keep moving" drive through a workday, stimulant-free motivation and energy, occasional improvements in verbal fluency and word recall, a modest mood lift with more stress resilience, and reduced brain fog on demanding cognitive work — though memory and learning gains are generally said to become clearest after several consecutive days rather than immediately.

Mixed and inconsistent reports (anecdotal, not clinical evidence): a substantial minority describe the effect as subtle to the point of being unnoticeable, sometimes calling it "not a nootropic you feel," and some report feeling flat or unfocused rather than sharper. The noticeable effect is also widely described as short — a handful of hours before it fades, prompting many to redose later in the day. Some long-term users report the benefit blunting with continuous daily use and choose to cycle on and off.

Reported downsides (anecdotal, not clinical evidence): because the most common route is intranasal, burning, stinging, or congestion right after dosing is one of the most frequently mentioned complaints, usually fading within ten to fifteen minutes. A notable share describe an afternoon or evening comedown into fatigue or sleepiness as the effect wears off, and a minority report irritability, restlessness, or overstimulation — more often when Semax is combined with caffeine or prescription stimulant medication, which several users say it noticeably potentiates. Headache and, less commonly, vivid dreams or disrupted sleep when dosed late in the day are also mentioned.

Cited cautions from the clinical literature:

• Sold only as an unregulated research chemical outside Russia and Ukraine. There is no required testing of identity, purity, sterility, or peptide content in research-grade Semax, and none of the published pharmacology was conducted on that consumer product.
• Neurotrophin and gene-expression effects are powerful and incompletely understood as a long-term habit. Semax rapidly and specifically changes expression of BDNF, NGF, and, in injury models, large numbers of immune and vascular genes ^[7][8][9]. What repeatedly driving that kind of gene expression does in a healthy human brain over months or years has simply not been studied.
• Interactions with stimulants and antidepressants are unstudied and biologically plausible. Semax inhibits enkephalin-degrading enzymes that normally break down the body's own opioid-like signaling peptides ^[12], and animal work shows it can meaningfully potentiate stimulant drug effects — consistent with community reports of irritability or anxiety when it is stacked with caffeine or ADHD medication.
• The primary route (intranasal) can irritate the nasal lining, particularly with more concentrated, non-pharmaceutical preparations whose sterility and pH are not controlled outside a licensed pharmacy ^[11].
• There is no established human dosing, cycling, or tolerance framework. All quantitative dosing in the published literature is expressed per kilogram in rats and mice; there is no validated human dosing schedule outside Russian clinical formulations, and community cycling practices are not backed by characterized receptor kinetics ^[11].
• Pregnancy, breastfeeding, and pre-existing medical conditions are entirely uncharacterized, and because Semax touches opioid-peptide signaling and drug-potentiation pathways, the risks for these groups cannot be predicted from the available data ^[12].

Where it fits in calm, focus and sleep research

Semax is the focus-end anchor on this desk — the compound with the most mechanistically coherent evidence, built on a specific, measurable binding site and a repeatable neurotrophin effect ^[9]. Where DSIP still carries an unresolved mechanism after four decades of study, Semax's open questions are different in character: strong rodent data, very little independent Western human replication, and a real, community-reported non-response rate of its own. Reading the two together maps the honest range of evidence quality across this desk's theme of calm, focus, and sleep. See the comparison page for the side-by-side.